US$ 24.56
dpp-4 inhibitors and glp-1 agonists dpp-4_inhibitors [TUSOM Specific actions of GLP-1 receptor
Description
3Assistant Professor, Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan

In the large SUSTAIN and PIONEER trials, only about 2060% of the CRP reduction was explained by weight and glycaemia
Diabetes Obes Metab 24(1):94105 Zaazouee MS et al (2022) Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes

13 GLP1-RAs have shown potential to reduce glycaemic variability while posing a low risk of hypoglycaemia

We calculated this by taking the product of the weights calculated from the conditional probabilities of treatment discontinuation or switching, administrative censoring (end of study period/end of registration with practice), and death by using the covariates listed above
Several studies have primarily evaluated the changes in cardiovascular risk biomarkers upon the use of GLP-1 RAs